These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36243666)

  • 81. [Vaccination against herpes zoster].
    Larsen CS; Helleberg M
    Ugeskr Laeger; 2021 Nov; 183(47):. PubMed ID: 34851258
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Fix J; Vielot NA; Lund JL; Weber DJ; Smith JS; Hudgens MG; Becker-Dreps S
    Vaccine; 2023 Jan; 41(1):49-60. PubMed ID: 36396511
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation.
    Baumrin E; Izaguirre NE; Bausk B; Feeley MM; Bay CP; Yang Q; Ho VT; Baden LR; Issa NC
    Blood Adv; 2021 Mar; 5(6):1585-1593. PubMed ID: 33710336
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.
    Hentzien M; Bonnet F; Bernasconi E; Biver E; Braun DL; Munting A; Leuzinger K; Leleux O; Musardo S; Prendki V; Schmid P; Staehelin C; Stoeckle M; Walti CS; Wittkop L; Appay V; Didierlaurent AM; Calmy A
    BMC Infect Dis; 2024 Mar; 24(1):329. PubMed ID: 38504173
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
    Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
    Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
    JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine.
    Hurley LP; O'Leary ST; Dooling K; Anderson TC; Crane LA; Cataldi JR; Brtnikova M; Beaty BL; Gorman C; Guo A; Lindley MC; Kempe A
    J Gen Intern Med; 2023 Mar; 38(4):986-993. PubMed ID: 35794307
    [TBL] [Abstract][Full Text] [Related]  

  • 88. ATAGI Targeted Review 2022: Vaccination for prevention of herpes zoster in Australia.
    Huang YA; Li-Kim-Moy J; Jayasinghe S; Chiu C; Macartney K; Liu B; Burns P; Giles M; Crawford N
    Commun Dis Intell (2018); 2023 Apr; 47():. PubMed ID: 37106452
    [TBL] [Abstract][Full Text] [Related]  

  • 89. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.
    Coretti S; Codella P; Romano F; Ruggeri M; Cicchetti A
    Int J Technol Assess Health Care; 2016 Jan; 32(4):233-240. PubMed ID: 27624398
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
    Bresse X; Annemans L; Préaud E; Bloch K; Duru G; Gauthier A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):393-406. PubMed ID: 23537397
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
    Lewis CY; Mishra K; Sun Y; Sechrist SJ; Arnold BF; Acharya NR
    Vaccine; 2023 May; 41(23):3493-3496. PubMed ID: 37150621
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials.
    Giannelos N; Francq B; Curran D
    Clin Drug Investig; 2024 May; 44(5):293-301. PubMed ID: 38662318
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
    Caldera F; Spaulding AC; Borah B; Moriarty J; Zhu Y; Hayney MS; Farraye FA
    Aliment Pharmacol Ther; 2023 Jun; 57(11):1326-1334. PubMed ID: 36896952
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
    Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
    PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Harpaz R; Ortega-Sanchez IR; Seward JF;
    MMWR Recomm Rep; 2008 Jun; 57(RR-5):1-30; quiz CE2-4. PubMed ID: 18528318
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.
    van Lier A; van Hoek AJ; Opstelten W; Boot HJ; de Melker HE
    BMC Health Serv Res; 2010 Aug; 10():237. PubMed ID: 20707884
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.
    Kim JH; Diaz-Decaro J; Jiang N; Hwang SJ; Choo EJ; Co M; Hastie A; Hui DSC; Irimajiri J; Lee J; Leung EM; Tang H; Tsuru T; Watson P; Wu Z; Yu CJ; Yuan Y; Zahaf T; Cunningham AL; Schuind A
    Hum Vaccin Immunother; 2021 Jul; 17(7):2050-2057. PubMed ID: 33606577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.